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ABSTRACT 
Objective: To assess the bacteriology of beta-lactamase (BL) 
enzyme activity in sputum of 40 patients with acute exacer- 
bation of chronic bronchitis (AECB). 
Methods: The microbiology, BL production by the different iso- 
lates, and BL contents in the sputum were determined, 
Results: Eighty-four isolates were recovered (2.1 isolates per 
specimen), 44 aerobic and facultative (1 .I isolates per speci- 
men), and 40 anaerobic (1 .O isolate per specimen). Aerobic 
bacteria were recovered in only 9 (225%) specimens, anaer- 
obic bacteria in 9 (22.5%), and mixed aerobic and anaerobic 
bacteria were found in 22 (55%). The predominant aerobic iso- 
lates were Streptococcus pneumoniae (15 isolates), Haemo- 
phi/us influenzae (1 I), Moraxella catarrbalis and Klebsiella 
pneumoniae (4 each). The predominant anaerobes were Pep- 
tostreptococcus sp. (19) Prevotella sp. (1 l), and Fusobac- 
terium sp.(6). Mixed flora were present in 25 (62.5%) 
specimens, and the number of isolates varied from 2 to 5 per 
specimen. Thirty-nine beta-lactamase-producing bacteria 
(BLPB) were isolated in 33 (82.5%) of the 40 cases. The pre- 
dominant aerobic BLPB were H. influenzae, M. catarrhalis, K. 
pneumoniae, Staphylococcus aureus, and Escherichia co/i. The 
predominant anaerobic BLPB were Prevotella sp. and Fusobac- 
terium sp. Beta-lactamase activity was detected in 26 (79%) 
of 33 of specimens in which BLPB were isolated, and in none 
of the seven specimens that did not harbor BLPB. 
Conclusions: The rapid detection of BL activity in sputum spec- 
imens may have implications for the antimicrobial management 
with AECB. 
Key Words: acute exacerbation of chronic bronchitis, beta- 
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Antimicrobial therapy plays an important role in the man- 
agement of acute exacerbation of chronic bronchitis 
(AECB), because bacteria may contribute to the perpet- 
uation and exacerbation of the illness.’ The major organ- 
isms recovered from the sputum of patients with AECB 
are Streptococcus pneumoniae, Haemophilus injluen- 
zae, and Moraxella catawbalis.1,2 
Growing resistance through the production of the 
enzyme beta-lactamase (BL), may make the management 
of AECB more difficult. It has been hypothesized that 
beta-lactamase-producing bacteria (BLPB), can protect 
themselves as well as non-BLPB from penicillins.“,* Beta- 
lactamase activity previously has been detected in expec- 
torated sputum of patients with lower respiratory tract 
infection,5-8 cystic fibrosis,’ and bronchitis.” However, 
the detection of BL activity was only correlated with the 
recovery of aerobic organisms (H. influenzae, M. 
catarrhalis, and Pseudomonas aeruginosa). 
The authors investigated the activity of BL in the spu- 
tum of patients of AECB, and correlated its presence with 
the recovery of aerobic as well as anaerobic bacteria in 
the expectorated sputum. 
PATIENTS AND METHODS 
The study included 40 patients (31 males; 9 females). Their 
ages ranged from 39 to 83 years (average, 53 y). All patients 
had symptoms consistent with AECB, specifically, cough, 
substernal pain during respiration or cough, and fever. 
None had received antimicrobial therapy in the 6 weeks 
prior to inclusion in the study. However, all had received 
numerous courses of antibiotics for ABCB in the previous 
2 years. Other inclusion criteria included a sputum smear 
with less than 10 squamous epithelial cells and more than 
25 leukocytes per low-power field. Sputum specimens 
were plated, within 10 minutes of collection, on media 
supportive of growth of aerobic and anaerobic bacteria, 
as previously described.r2 Aerobic and anaerobic bacte- 
ria were identified by conventional methods. 13,‘* Beta-lac- 
tamase activity was determined for all isolates using the 
chromogenic cephalosporin analogue 87/312 method.15 
Beta-lactamase activity in the sputum was determined 
by separating the supernatant by centrifugation for 15 min- 
utes at 20,000 g. Beta-lactamase activity of the supernatant 
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Table 1. Organisms Isolated in 40 Expectorated Sputum Specimens and Beta-Lactamase 
Detection in Patients with Acute Bacterial Exacerbation of Chronic Bronchitis 
Patient Number 
isolated Organisms 
Aerobic organisms (n = 44) 
Haemophilus influenzae 
Moraxella catarrhalis 
Streptococcus pneumoniae 
Staphylococcus aureus 
Klebsiella pneumoniae 
Acinetobacter calcoaceticus 
Pseudomonas aeruginosa 
Escherichia co/i 
1 234 56 789 10 77 12 13 14 15 16 77 18 19 20 
+ + + - - + + 
+ + + 
- - - 
+ 
+ + + 
+ 
+ + 
Anaerobic organisms (n = 40) 
Peptostreptococcus sp. 
Prevotella sp. 
Porphyromonas sp. 
Fusobacterium sp. 
- - - - - 
- + + - + 
+ 
+ + + - 
Beta-lactamase activity detected in sputum Y Y N Y Y Y N Y Y YYYYNN NYYYY 
- = non-beta-lactamase-producing organism isolated; + = a beta-lactamase-producing organism isolated: Y = yes; N = No. (table continues next page) 
was assessed with nitrocefin (Glaxo, Middlesex, England), 
which turns red after exposure to BL. The reaction mixture 
consisted of nitrocefin dissolved in phosphate-buffered 
saline (pH, 7.2) at a concentmtion of 500 ug/mL. The nitro 
cefm solution (10 FL) was added to 10 PL of BL solution 
(Difco Laboratories, Detroit, MD or to 10 uL of pus super- 
natant. Negative controls contained 10 PL of nitrocefin 
plus 10 uL of either undiluted enzyme-negative sinus fluid 
supernatant or trypticase soy broth. A change from yellow 
to red usually became apparent within 5 to 12 minutes. 
RESULTS 
Microorganisms were isolated from all specimens. Eighty- 
four isolates were recovered from the 40 patients (2.1 
isolates per specimen), 44 aerobic and facultative (1.1 iso- 
lates per specimen), and 40 anaerobic (1.0 isolate per 
specimen) (Table 1). Aerobic bacteria were recovered in 
9 (22.5) specimens, anaerobic bacteria in 9 (22.5%) and 
mixed aerobic and anaerobic bacteria were found (55%) 
(Table 2). 
The predominant aerobic isolates were Spneumo- 
niae (15 isolates), H. infuenzae (1 l), M. cutarrhalis and 
Klebsiella pneumoniae (4 each), and Staphylococcus 
aureus and Escherichia coli (3 each). The predominant 
anaerobes were Peptostreptococcus sp. (19) Prevotella 
sp. (1 l), Fusobacterium sp. (6) and Porphyromonas sp. 
(4). Mixed flora were present in 25 (62.5%) specimens, 
in which the number of isolates varied from 2 to 5 per 
specimen. Single organisms were recovered from 15 
(37.5%) specimens (see Table 1). 
Thirty-nine BLPB were isolated in 33 (82.5%) of the 
40 cases (see Table 1). Twenty-four of the 44 (55%) aer- 
obic and facultative bacteria produced BL. The aerobic 
BLPB were H. influenzae (6/l 1,55%), M. catarrhalis and 
K. pneumoniae (4/4 in both), S. aureus and E. coli (3/3 
in both), and Pseudomonas aeruginosa and Acineto- 
batter calcoaceticus (2/2 in both). Fifteen of the 40 
(37.5%) anaerobic bacteria produced BL. The anaerobic 
BLPB were Prevotellu sp. (8/l 1,73%), Fusobacterium sp. 
(5/6,83%), and Porpbyromonas sp. (2/4,50%). 
Beta-lactamase activity was detected in 26 (79%) of 
the 33 specimens in which BLPB were isolated, and in 
none of the seven specimens that did not harbor BLPB 
(see Table 2). Of the 19 specimens that harbored aerobic 
BLPB only, BL activity was detected in 16 (84%); of the 9 
that had anaerobic BLPB only, BL activity was found in 5 
(55%) and BL activity was present in all 5 specimens that 
had both aerobic and anaerobic BLPB. 
DISCUSSION 
This study confirms the findings of previous studies that 
demonstrate the recovery of S. pneumoniae, H. influen- 
zae, M. catarrhalis, and Enterobacteriaceae from the 
Table 2. Beta-Lactamase Activity in Sputum Specimen 
in Relation to the Presence of Enzyme-Producing 
Bacteria Recovered from the Sputum 
Specimens in Which Beta- 
Type of BLPB Specimens Lactamase Activity Was 
isolates Recovered (n = 40) Detected (n = 26) (78%) 
None detected 7 0 (0) 
Aerobic only recovered 19 16 (84) 
Anaerobic only 9 5 (55) 
Aerobic and anaerobic 
recovered 5 5 (100) 
BLPB = beta-lactamase-producing bacteria. 
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Table 1. Organisms Isolated in 40 Expectoratal Sputum Specimens and Beta-Lactamase 
Detection in Patients with Acute Bacterial Exacerbation of Chronic Bronchitis (continued) 
lsolafed Organisms 
Patient Number Total No. 
Bacteria 
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 (n = 84) 
Aerobic organisms (n = 44) 
Haemophilus influenzae 
Moraxella ca tarrhalis 
Streptococcus pneumoniae 
Staphylococcus aureus 
Klebsiella pneumoniae 
Acinetobacter calcoaceticus 
Pseudomonas aeruginosa 
Escherichia co/i 
+ - 11 
+ 4 
- - - - 15 
+ + 3 
+ 4 
+ 2 
+ + 2 
f 3 
Anaerobic organisms (n = 40) 
Peptostreptococcus sp. 
Prevotella sp. 
Porphyromonas sp. 
Fusobacterium sp. 
- - - - - - - - - 19 
+ + + + + 11 
+ 4 
+ + 6 
Beta-lactamase activity detected in sputum N N NYYYYYYYYNYNNYNYNN 
- = non-beta-lactamase-producing organism isolated; + = a beta-lactamase-producing organism isolated; Y = yes; N = No. 
sputum of patients with AECB.‘z2 However, it also demon- 
strates the isolation of anaerobic bacteria of oral flora 
origin in the sputum of over 75% of the patients. Anaer- 
obic bacteria can colonize the bronchial tree, and are 
associated with pneumonia in children intubated after 
tracheostomy. l6 These organisms have also been associ- 
ated with pulmonary infections of aspiration nature, 
which include aspiration pneumonia, lung abscesses, and 
emyema. 17,” Although the pathogenic role of these anaer- 
obic bacteria in AECB is difficult to ascertain and their 
potential oral origin cannot be excluded, their ability to 
produce BL may contribute to the overall presence of 
this enzyme in the sputum. 
The recovery of BLPB is not surprising, since all of 
the patients in this study had multiple courses of antimi- 
crobial therapy for previous episodes of AECB that might 
have selected for BLPB.‘” The ability to detect BL activ- 
ity in the expectorated sputum in 26 (79%) of 33 speci- 
mens in which BLPB were isolated suggests that this 
enzyme not only is able to protect the BLPB but also can 
degrade penicillin in bronchial secretions, thus protect- 
ing penicillin-sensitive organisms. 
The rapid detection of BL activity in sputum speci- 
mens using available methods can be performed prior to 
recovery of organisms, which may take up to 48 hours. 
This testing can be performed even in locations where 
microbiologic laboratory services are not available, as 
may be the case in developing countries. 
Despite the common practice of treating an AECB 
with antimicrobial agents, the precise role of microbial 
pathogens is unclear. Because the lower respiratory tract 
of patients with chronic obstructive pulmonary disease 
(COPD) is frequently colonized with bacteria, the prin- 
cipal problem entails differentiating bronchial coloniza- 
tion from infection. Even when invasive diagnostic tech- 
niques (bronchoscopy with protected specimen brush) 
were used, a “significant quantity” of respiratory 
pathogens was found in approximately 50% of cases.‘.2 
Because of the difficulty of distinguishing between bac- 
terial and nonbacterial exacerbation, most patients have 
been treated with empirical antimicrobials directed 
against the most frequently isolated pathogens. 
The isolation of BLPB from sputum specimens of 
patients with AECB and the ability to actually measure the 
activity of the BL enzyme in the sputum raise the question 
of whether the treatment of AECB with beta-lactamase sus- 
ceptible antibiotics is adequate in all instances, and 
whether therapy when indicated should be directed at the 
eradication of these organisms whenever they are present. 
Further studies that would evaluate the efficacy of antimi- 
crobials effective against the recovered aerobic and anaer- 
obic BLPB in AECB are warranted. 
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